Evidence map›Paper›PMID 39066525›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2024

Spore Oil enhances the effect of cyclophosphamide inhibiting programmed death-1 and prolongs the survival of H22 tumor-bearing mice.

Jiang Zhaojian, Cai Hongfei, Yuan Cheng, Cao Lin, X U Wendong, Han Yaming, Zhang Qin, L I Jing, Wang Qin, Liu Juyan

Abstract read
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Oxidative Stability and Quality Deterioration ofFoods (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiang ZhaojianGuangzhou HanFang Pharmaceutical Company Limited, National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation, Guangdong Provincial Key Laboratory of Medicinal Lipids, Guangzhou 510240, China.
Cai HongfeiGuangzhou HanFang Pharmaceutical Company Limited, National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation, Guangdong Provincial Key Laboratory of Medicinal Lipids, Guangzhou 510240, China.
Yuan ChengGuangzhou HanFang Pharmaceutical Company Limited, National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation, Guangdong Provincial Key Laboratory of Medicinal Lipids, Guangzhou 510240, China.
Cao LinGuangzhou HanFang Pharmaceutical Company Limited, National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation, Guangdong Provincial Key Laboratory of Medicinal Lipids, Guangzhou 510240, China.
X U WendongGuangzhou HanFang Pharmaceutical Company Limited, National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation, Guangdong Provincial Key Laboratory of Medicinal Lipids, Guangzhou 510240, China.
Han YamingGuangzhou HanFang Pharmaceutical Company Limited, National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation, Guangdong Provincial Key Laboratory of Medicinal Lipids, Guangzhou 510240, China.
Zhang QinGuangzhou HanFang Pharmaceutical Company Limited, National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation, Guangdong Provincial Key Laboratory of Medicinal Lipids, Guangzhou 510240, China.
L I JingGuangzhou HanFang Pharmaceutical Company Limited, National Engineering Research Center of Pharmaceutical Processing Technology of Traditional Chinese Medicine and Drug Innovation, Guangdong Provincial Key Laboratory of Medicinal Lipids, Guangzhou 510240, China.
Wang QinZhongshan Medical College, Sun Yat-sen University, Guangzhou 510080, China.
Liu JuyanGuangzhou Pharmaceutical Holdings Limited, Guangzhou 510130, China.

Funding

Guangdong Province Key Areas Research and Development Program Project : Research and Development on Innovative Key Technologies and Intelligent Production Equipment about Processing, Decoction, Extraction and Separation of Traditional Chinese Medicine 2020B1111120002Key Laboratory Project of Pharmaceutical Lipids in Guangdong Province : Assessment of Enterprise-Class Key Laboratory of Guangdong Province 2020B1212070024Ministry of Science and Technology of China: Evaluation, Re-examination, Promotion and Demonstration of Complete Sets of Technical Equipment for Efficient and Energy-Saving Extraction and Separation of Traditional Chinese Medicine 2017YFC1703104
6 · The paper itself

Abstract

objectiveTo investigate the effect of

methodsAllograft H22 hepatocellular carcinoma mouse model was applied to investigate the effect of GLSO on the tumor growth and survival of animals, and Kaplan-Meier survival analysis was used to analyze the life span. Plasma biochemical examination was used to determine the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea (UREA) and creatinine (CRE). Western blot analysis was performed to detect Programmed Death-1 (PD-1), Programmed Death Ligand 1 (PD-L1), Janus Kinase 2 (JAK2), phosphorylated Signal Transducer and Activator of Transcription 3 (p-STAT3), and Signal Transducer and Activator of Transcription 3 (STAT3) expression.

resultsGLSO increased the anti-tumor effect of CTX and prolonged the survival of H22 tumor-bearing mice treated with CTX. Meanwhile, GLSO increased the thymus index and showed no obvious toxicity to liver functions of animals. GLSO also decreased the level of UREA in H22 tumor-bearing mice treated with CTX. Furthermore, GLSO could inhibit the expression of PD-1 in spleen, which was independent of JAK2 expression and STAT3 phosphorylation. However, GLSO did not affect the expression of PD-L1, JAK2, and p-STAT3 in tumor tissue.

conclusionGLSO could strengthen the anti-tumor effect of CTX and prolong the life span of H22 tumor-bearing mice, while the underlying mechanism might be relevant to the amelioration effect of thymus function and inhibition of PD-1 expression in spleen. Furthermore, these findings implied the promising role of GLSO in combination with CTX to extend the survival of patients in clinical chemotherapy of hepatocellular carcinoma.

Indexed as

CyclophosphamideLiver NeoplasmsProgrammed Cell Death 1 ReceptorAnimalsB7-H1 AntigenCarcinoma, HepatocellularCell Line, TumorDrugs, Chinese HerbalHumansJanus Kinase 2MaleMiceSTAT3 Transcription FactorB7-H1 AntigenCyclophosphamideDrugs, Chinese HerbalJanus Kinase 2Pdcd1 protein, mouseProgrammed Cell Death 1 ReceptorSTAT3 Transcription Factorcarcinoma, hepatocellularcyclophosphamideGanoderma Lucidum Spore Oilprogrammed cell death 1 receptorsurvival

Identifiers

PMID39066525
PMCPMC11337259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.